Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03971045
Title Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES)
Acronym PERICLES
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors European Institute of Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Istituto Europeo di Oncologia RECRUITING Milan 20141 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field